Earnings

Which of 2 stocks would appeal to long-term investors? Sarepta Therapeutics, Inc. (SRPT), ZIOPHARM Oncology, Inc. (ZIOP)

The shares of Sarepta Therapeutics, Inc. have increased by more than 63.25% this year alone. The shares recently went down by -2.83% or -$2.65 and now trades at $90.83. The shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), has jumped by 4.83% year to date as of 05/21/2018. The shares currently trade at $4.34 and have been able to report a change of -1.81% over the past one week.

The stock of Sarepta Therapeutics, Inc. and ZIOPHARM Oncology, Inc. were two of the most active stocks on Monday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of SRPT is -14.20% while that of ZIOP is 55.30%. These figures suggest that ZIOP ventures generate a higher ROI than that of SRPT.

Cash Flow

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, SRPT’s free cash flow per share is a negative -0.03, while that of ZIOP is also a negative -0.31.

Liquidity and Financial Risk



The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for SRPT is 13.40 and that of ZIOP is 7.20. This implies that it is easier for SRPT to cover its immediate obligations over the next 12 months than ZIOP.

Valuation

SRPT currently trades at a P/B of 7.56, and a P/S of 28.84 while ZIOP trades at a P/S of 125.57. This means that looking at the earnings, book values and sales basis, SRPT is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of SRPT is currently at a 2.67% to its one-year price target of 88.47. Looking at its rival pricing, ZIOP is at a -40.14% relative to its price target of 7.25.




When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), SRPT is given a 1.80 while 2.50 placed for ZIOP. This means that analysts are more bullish on the outlook for ZIOP stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for SRPT is 7.34 while that of ZIOP is just 32.19. This means that analysts are more bullish on the forecast for SRPT stock.

Conclusion

The stock of Sarepta Therapeutics, Inc. defeats that of ZIOPHARM Oncology, Inc. when the two are compared, with SRPT taking 6 out of the total factors that were been considered. SRPT happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, SRPT is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for SRPT is better on when it is viewed on short interest.

Previous ArticleNext Article

Related Post

Choosing Between Hot Stocks: CF Industries Holding... The shares of CF Industries Holdings, Inc. have decreased by more than -2.66% this year alone. The shares recently went up by 0.36% or $0.15 and now t...
A Side-by-side Analysis of Ball Corporation (BLL) ... Ball Corporation (NYSE:BLL) shares are up more than 10.43% this year and recently decreased -0.72% or -$0.3 to settle at $41.45. International Paper C...
Should You Buy Cleveland-Cliffs (CLF) or Fairmount... Cleveland-Cliffs Inc. (NYSE:CLF) shares are down more than -17.00% this year and recently increased 2.35% or $0.16 to settle at $6.98. Fairmount Santr...
A Side-by-side Analysis of Prudential Financial, I... Prudential Financial, Inc. (NYSE:PRU) shares are down more than -7.04% this year and recently decreased -0.90% or -$0.97 to settle at $106.89. Lincoln...
Uncovering the next great stocks: NetApp, Inc. (NT... The shares of NetApp, Inc. have increased by more than 19.41% this year alone. The shares recently went up by 3.90% or $2.48 and now trades at $66.06....